183 filings
Page 8 of 10
8-K
siow18f1
23 May 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
3uha39laqk8 hj59uqg9
10 May 17
KemPharm, Inc. Reports First Quarter 2017 Results
12:00am
8-K
18zuve91tbv 2i
28 Mar 17
Changes in Registrant's Certifying Accountant
12:00am
8-K
1srg5ra1 mzh0
9 Mar 17
KemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results
12:00am
8-K
rnvmr84ejvh2r
15 Feb 17
Departure of Directors or Certain Officers
12:00am
8-K
yqj77 ogjz
9 Jan 17
Regulation FD Disclosure
12:00am
8-K
xs2xsfnh7g6a
14 Dec 16
KemPharm’s KP415, An Investigational Prodrug of D-Methylphenidate, Completes Phase 1 Proof-of-Concept Trial for the Treatment of ADHD
12:00am
8-K
po2x2abnpboa0 3y
9 Nov 16
KemPharm, Inc. Reports Third Quarter 2016 Results
12:00am
8-K
06215e ikqn
18 Oct 16
KemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion® Abuse-Deterrent Technology
12:00am
8-K
2r3l11qk3j6uk3faxcmm
3 Oct 16
Entry into a Material Definitive Agreement
12:00am
8-K
cn0nw3
21 Sep 16
Other Events
12:00am
8-K
a0dsg fb1h7
15 Sep 16
KemPharm, Inc. Provides Corporate and Clinical Update
12:00am
8-K
89vl plxs0a4a
11 Aug 16
Other Events
12:00am
8-K
lf7a y5a5a6312a
10 Aug 16
KemPharm, Inc. Reports Second Quarter 2016 Results
12:00am
8-K
dbgixdqnwf0kov
28 Jun 16
Other Events
12:00am
8-K
sy1ikf
13 Jun 16
FDA Issues Complete Response Letter for ApadazTM New Drug Application
12:00am
8-K
umrooko714 jctnh
9 Jun 16
KemPharm Files NDA Amendment Request with FDA for ApadazTM
12:00am
8-K
ci0ympje
25 May 16
Submission of Matters to a Vote of Security Holders
12:00am
8-K
v0gx6kg
12 May 16
KemPharm, Inc. Reports First Quarter 2016 Results
12:00am
8-K
2jeu3
6 May 16
Statement Regarding FDA Advisory Committee Meeting on KemPharm’s Abuse-Deterrent Product Candidate ApadazTM
12:00am